Elanco Animal Health Inc
NYSE:ELAN
Relative Value
The Relative Value of one
ELAN
stock under the Base Case scenario is
21.61
USD.
Compared to the current market price of 24.52 USD,
Elanco Animal Health Inc
is
Overvalued by 12%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ELAN Competitors Multiples
Elanco Animal Health Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Elanco Animal Health Inc
NYSE:ELAN
|
12.1B USD | 2.7 | 338.7 | 17.2 | 64.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD | 17.7 | 57 | 38.2 | 41 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD | 6 | 21.1 | 14.7 | 18 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF | 4.7 | 30.7 | 12.9 | 15.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD | 4.6 | 15.5 | 10.9 | 12.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF | 5.3 | 20.5 | 12.9 | 16.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP | 5.1 | 31.6 | 15.1 | 22.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.3 | 13.1 | 9.2 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD | 2.4 | 15.6 | 7.8 | 10.7 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR | 1.8 | 8.3 | 7.7 | 7.7 |